2018-01-05 Modus Therapeutics to Present at Biotech Showcase 2018 in San Francisco

2017-12-20 Modus Therapeutics announces paper in PLOS ONE demonstrating the anti-adhesive properties of sevuparin in malaria patients

Annual Shareholders Meeting Update (in Swedish)

2017-09-14 Professor Thomas Knittel appointed Modus CMO

2017-06-14 The Board of Directors’ Proposed Resolution Regarding Issue of Warrants

2017-09-13 Modus Therapeutics to present at SCD Therapeutics Conference in New York

2017-05-24 Notice of Annual General Meeting of Modus Therapeutics Holding AB (publ) (in Swedish)

2017-04-24 Modus Therapeutics appoints Ellen K. Donnelly, Ph.D. as CEO

2017-02-20 Modus Therapeutics raises SEK 32 million to support further development of sevuparin for sickle cell disease

2016-12-01 Modus Therapeutics to present poster at 58th ASH Annual Meeting in San Diego

2016-11-15 Independent DSMB endorses inclusion of adolescents in ongoing clinical study with sevuparin in Sickle Cell Disease

2016-10-20 Dilaforette changes name to Modus Therapeutics and announces intention to conduct an Initial Public Offering

2016-11-07 Modus Therapeutics announces two new U.S. patents for its candidate drug sevuparin

2016-06-19 Modus poster presented at EHA Congress

2016-02-08 Modus Therapeutics appoints new VP of Development

2016-02-16 Modus Therapeutics signs collaboration agreement with Arabian Gulf University (Bahrain) for Phase 2 clinical development of sevuparin for Sickle Cell Disease

2015-11-19 Modus Therapeutics strengthens its board

2015-11-13 Modus Therapeutics to attend BIO-Europe 2015

2015-10-13 Modus Therapeutics and Ergomed Initiate Phase II Clinical Trial with Modus’ Sevuparin in Sickle-Cell Disease

2015-09-01 Modus Therapeutics to present at Nordic Life Science Days 2015

2015-08-02 New HQ in Stockholm for Modus Therapeutics

2015-02-19 Modus Therapeutics Announces Co-Development Agreement with Ergomed for Sickle-Cell Disease Treatment

2015-03-20 Modus Therapeutics receives Orphan Drug Designation in the U.S. for sevuparin in Sickle-Cell Disease

2015-01-19 Modus Therapeutics receives positive COMP opinion on Orphan Drug Designation in the EU for sevuparin in Sickle-Cell Disease

2014-05-30 Modus Therapeutics presents results from exploratory Phase II clinical trial in uncomplicated malaria

2014-01-22 Christina Herder appointed CEO of Modus Therapeutics

2013-01-30 Modus Therapeutics – Phase II study with sevuparin for the treatment of severe malaria initiated

2012-11-02 Modus Therapeutics is granted SEK 2.85m for development of sevuparin for the treatment of severe malaria